BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1196 related articles for article (PubMed ID: 25948774)

  • 21. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
    Wang J; Li G; Wang Y; Tang S; Sun X; Feng X; Li Y; Bao G; Li P; Mao X; Wang M; Liu P
    Oncotarget; 2015 Dec; 6(42):44579-92. PubMed ID: 26625311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo.
    Saraswati S; Agrawal SS
    Cancer Lett; 2013 May; 332(1):83-93. PubMed ID: 23348691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-permeable iron inhibits vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis.
    Kir D; Saluja M; Modi S; Venkatachalam A; Schnettler E; Roy S; Ramakrishnan S
    Oncotarget; 2016 Oct; 7(40):65348-65363. PubMed ID: 27589831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
    Lai XM; Liu SY; Tsai YT; Sun GH; Chang SY; Huang SM; Cha TL
    Oncotarget; 2017 Jul; 8(30):49713-49724. PubMed ID: 28572533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aromatic Hydrocarbon Receptor Suppresses Prostate Cancer Bone Metastasis Cells-Induced Vasculogenesis of Endothelial Progenitor Cells under Hypoxia.
    Huang S; Guo Y; Jacobi A; Li Z; Huang S; He J; Liu X; Tang Y
    Cell Physiol Biochem; 2016; 39(2):709-20. PubMed ID: 27448695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha.
    Forooghian F; Das B
    Am J Ophthalmol; 2007 Nov; 144(5):761-8. PubMed ID: 17869204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.
    Goel HL; Pursell B; Shultz LD; Greiner DL; Brekken RA; Vander Kooi CW; Mercurio AM
    Cell Rep; 2016 Mar; 14(9):2193-2208. PubMed ID: 26923603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
    Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
    Young E; Miele L; Tucker KB; Huang M; Wells J; Gu JW
    Cancer Biol Ther; 2010 Oct; 10(7):703-11. PubMed ID: 20686367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
    Knowles HJ; Athanasou NA
    J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells.
    Ciccone V; Terzuoli E; Donnini S; Giachetti A; Morbidelli L; Ziche M
    J Exp Clin Cancer Res; 2018 Dec; 37(1):311. PubMed ID: 30541574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
    Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
    Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.
    Bougatef F; Quemener C; Kellouche S; Naïmi B; Podgorniak MP; Millot G; Gabison EE; Calvo F; Dosquet C; Lebbé C; Menashi S; Mourah S
    Blood; 2009 Dec; 114(27):5547-56. PubMed ID: 19837976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of VEGF expression through interruption of the HIF‑1α and Akt signaling cascade modulates the anti‑angiogenic activity of DAPK in ovarian carcinoma cells.
    Park ST; Kim BR; Park SH; Lee JH; Lee EJ; Lee SH; Rho SB
    Oncol Rep; 2014 Feb; 31(2):1021-9. PubMed ID: 24337450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.